MOAbased
MOAbased is a term used to describe medical products, therapies, or research approaches that rely on monoclonal antibodies (mAbs). The designation is commonly written as mAb-based and MOAbased, referring to strategies that use antibodies derived from a single clone to recognize a specific antigen with high precision. Monoclonal antibodies are produced by hybridoma technology or recombinant methods and can be engineered to be murine, chimeric, humanized, or fully human to reduce immunogenicity. They may be used as naked antibodies, as antibody-drug conjugates, or as bispecific constructs.
Mechanisms of action for MOAbased therapies include binding to cell-surface or soluble targets to block signaling,
Applications span oncology, autoimmune and inflammatory diseases, infectious diseases, and diagnostic assays. Examples of well-known mAb-based
Manufacturing complexity, cost, and regulatory oversight are notable considerations. Biosimilars offer cost-competitive alternatives to originator products.